Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Pfizer’s $2.3B bet ends in failure as CD47 blocker scrapped
The Big Pharma has abandoned the second and final clinical-stage candidate from the Trillium acquisition.
James Waldron
May 5, 2026 9:15am
Janux axes solid tumor T-cell engager after poor ph. 1 showing
Apr 28, 2026 4:15am
Terremoto takes $108M series C to fuel trials of AKT1 inhibitors
Apr 15, 2026 7:43am
Pfizer drops another early cancer candidate from Seagen
Mar 19, 2026 12:56pm
Ono’s Deciphera drops early-stage solid tumor drug
Mar 3, 2026 7:47pm
As CAR-T gains ground on solid tumors, red tape blocks progress
Feb 26, 2026 3:08pm
